July 6, 2018

Hidden Conflicts? Pharma Payments to FDA Advisers After Drug Approvals Spark Ethical Concerns

(Science) – Brilinta fits a pattern of what might be called pay-later conflicts of interest, which have gone largely unnoticed—and entirely unpoliced. In examining compensation records from drug companies to physicians who advised FDA on whether to approve 28 psychopharmacologic, … Read More

Recommended Reading